Abstract
Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have